Eli Lilly’s Mounjaro (Tirzepatide), an American weight-loss and diabetes medication, has officially launched in India, offering a promising solution to tackle the country’s rising obesity and diabetes rates. For individuals looking to lose weight without radically changing their diet, Mounjaro may provide an effective alternative.
How Mounjaro Works
Mounjaro operates by activating two hormones, GIP and GLP-1, which are responsible for regulating blood sugar levels and controlling appetite. By mimicking these hormones, Mounjaro signals the brain that the body is full, reducing hunger and leading to a feeling of satiety. This allows individuals to feel fuller for longer, helping to curb overeating.
Effective Weight Loss
In a global study, participants who used Mounjaro along with a balanced diet and regular exercise experienced impressive results. Over a 16-week period, they lost approximately 10 kilograms, demonstrating the drug’s potential for weight loss.
Affordability in India
Mounjaro has been priced strategically for the Indian market. The cost of the drug is significantly lower than its price in the U.S.:
- Rs 4,375 ($50.67) for a 5 mg vial
- Rs 500 ($40.54) for a 2.5 mg vial
For a 5 mg dose, the monthly cost would be around Rs 16,000 ($200). In comparison, Mounjaro costs over $1,000 per month in the U.S., making it more affordable for Indian patients.
Potential Benefits Beyond Weight Loss
In addition to weight loss, Mounjaro has shown potential in reducing addictive behaviors like smoking and alcohol consumption. Some studies suggest it may also lower the risk of heart disease and Alzheimer’s. However, side effects such as nausea, vomiting, and diarrhea have been reported, and there is a rare risk of thyroid cancer. As noted by billionaire Nikhil Kamath, there are still many unknowns about the long-term effects of these medications.
Market Impact
The launch of Mounjaro gives Eli Lilly a competitive edge in India, particularly as Novo Nordisk’s Wegovy, another popular weight-loss drug, has been approved but is not yet available in the country. The success of Mounjaro in the Indian market could disrupt various industries, including food, beverage, and insurance sectors, similar to the shifts seen in the U.S. where GLP-1 drug users reduced food purchases and alcohol consumption.
In summary, Mounjaro’s entry into India provides a promising solution for weight loss, offering significant benefits at a lower cost than in Western markets. However, potential users should be aware of possible side effects and ensure they use the drug in conjunction with a healthy lifestyle.
Related Topics:
Which Weight Loss Injection Is Cheapest
